The SNTA trial is not blinded. The company sure had the data in hand for weeks last time as they talked the stock from 4 to 8 w/ wall street analysts in June. No reason to believe anything different is happening this time.Good points. didn't show/discuss the subgroup data - are they reversing and considering phase 3 in all adeno? mentioned OS benefit in all adeno specifically this timeI don't think they had definitively ruled out Phase 3 including all adeno before, did they?